Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review

2018 ◽  
Vol 25 (8) ◽  
pp. 920-929 ◽  
Author(s):  
N. Goossens ◽  
C. de Vito ◽  
A. Mangia ◽  
S. Clément ◽  
G. Cenderello ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Multi Centre Study ◽  
Centre Study ◽  
B Virus

Prevalence of HIV, hepatitis B virus, and hepatitis C virus among incarcerated people in Iran: a systematic review and meta-analysis

Public Health ◽  
2022 ◽  
Vol 203 ◽  
pp. 75-82
Author(s):  
S. Mehmandoost ◽  
M. Khezri ◽  
G. Mousavian ◽  
F. Tavakoli ◽  
F. Mehrabi ◽  
...  
Keyword(s):  
Systematic Review ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Meta Analysis ◽  
B Virus

scholarly journals Chronic Liver Disease in Ethiopia with a Particular Focus on the Etiological Spectrums: A Systematic Review and Meta-Analysis of Observational Studies

2021 ◽  
Vol 2021 ◽  
pp. 1-14
Author(s):  
Behailu Terefe Tesfaye ◽  
Temesgen Mulugeta Feyissa ◽  
Azmeraw Bekele Workneh ◽  
Esayas Kebede Gudina ◽  
Mengist Awoke Yizengaw
Keyword(s):  
Systematic Review ◽  
Hepatitis C Virus ◽  
Liver Disease ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Chronic Liver Disease ◽  
Meta Analysis ◽  
Chronic Liver ◽  
B Virus

Background. In Ethiopia, chronic liver disease (CLD) is the 7th leading cause of death, accounting for about 24 deaths per 100000 populations in 2019. Despite its burden, there is a lack of compiled pieces of evidence on CLD in the country. Thus, this systematic review and meta-analysis is intended to provide the pooled estimates of CLD etiologies and mortality rate in CLD patients in Ethiopia. Method. PubMed, Google Scholar, ScienceDirect, institutional repositories, national digital library, and the bibliography of the eligible articles information were the source of data for the present review. The keywords “hepatitis, chronic” [Mesh], “end-Stage Liver Disease” [Mesh], “chronic liver disease”, “liver cirrhosis” [Mesh], and “Ethiopia” were used for the searches. Overall, we retrieved 199 records and 12 were included in this review. We used the DerSimonian-Laird random-effects models to perform the meta-analysis. We conducted subgroup and meta-regression analyses to account for the heterogeneity of the estimates. Result. Hepatitis B virus, alcohol, and hepatitis C virus are the three most common etiologies of CLD in Ethiopia accounting for a pooled estimate of 40.0% [95% CI: 29.0, 51.0, I2 = 96.3, p < 0.001 ], 17.0% [95% CI: 9.0, 25.0, I2 = 96.7, p < 0.001 ], and 15.0% [95% CI: 9.0, 21.0, I2 = 95.8, p < 0.001 ], respectively. Unidentified etiology report has a substantial contribution accounting for an estimated pooled proportion of 45% [95% CI: 34.0, 56.0%, Q = 32.08, p < 0.001 , I2 = 87.53] of the CLD cases in the country. On the other hand, the overall hospital mortality rate in CLD patients is 25.0% [95% CI: 2.0, 47.0, I2 = 94.6, p < 0.001 ] in Ethiopia. Conclusion. Hepatitis B virus, hepatitis C virus, and alcohol are the three most common contributors to CLD cases in Ethiopia. The authors warrant routine screening and strengthening of preventive and treatment programs for viral hepatitis B and C, further enhancing the alcohol policy of the country.

scholarly journals Risk of reactivation of hepatitis B virus (HBV) and tuberculosis (TB) and complications of hepatitis C virus (HCV) following Tocilizumab therapy: A systematic review to inform risk assessment in the COVID era

2021 ◽  
Author(s):  
Cori Campbell ◽  
Monique Andersson ◽  
M. Azim Ansari ◽  
Olivia Moswela ◽  
Siraj A Misbah ◽  
...  
Keyword(s):  
Systematic Review ◽  
Risk Assessment ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Safety Data ◽  
Individual Risk ◽  
B Virus ◽  
Individual Risk Assessment

Tocilizumab (TCZ), an IL-6 receptor antagonist, is used in the treatment of COVID. However, this agent carries a 'black box' warning for infection complications, which may include reactivation of tuberculosis (TB) or hepatitis B virus (HBV), or worsening of hepatitis C virus (HCV). Due to the pace of clinical research during the COVID pandemic, prospective evaluation of these risks has not been possible. We undertook a systematic review, generating mean cumulative incidence estimates for reactivation of HBV and TB at 3.3% and 4.3%. We could not generate estimates for HCV. These data derive from heterogeneous studies pre-dating the COVID outbreak, with differing epidemiology and varied approaches to screening and prophylaxis. We underline the need for careful individual risk assessment prior to TCZ prescription, and present an algorithm for clinical stratification. There is an urgent need for ongoing collation of safety data as TCZ therapy is used in COVID.

Alkoholabstinenz allein verbessert die Leberfunktion und verlängert das Überleben bei der alkoholischen Lebererkrankung!

2016 ◽  
Vol 62 (6) ◽  
pp. 396-400 ◽  
Author(s):  
Helmut K. Seitz ◽  
Tatjana Arslic-Schmitt
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
B Virus ◽  
Alkoholische Lebererkrankung ◽  
Alkoholische Steatohepatitis

Zusammenfassung. Zielsetzung: Im Folgenden soll dargelegt werden, dass Alkoholkarenz sowohl die Leberfunktion als auch das Überleben in jedem Stadium einer alkoholischen Lebererkrankung günstig beeinflusst. Ergebnisse: Täglicher Alkoholkonsum von mehr als 25 Gramm reinen Alkohols, etwas mehr als ¼ Liter Wein beim Mann und etwa die Hälfte bei der Frau sind, mit einem erhöhten Risiko für eine alkoholische Lebererkrankung (ALE) behaftet. Die ALE besteht aus einem breiten Spektrum von histopathologischen Veränderungen. Sie beginnt immer mit einer alkoholischen Fettleber, die sich in eine alkoholische Steatohepatitis weiterentwickeln kann. Fortgeschrittene Formen der ALE beinhalten die Leberfibrose, die Leberzirrhose und das hepatozelluläre Karzinom. In der Behandlung jeder Form der ALE ist die Alkoholabstinenz von zentraler Bedeutung. Ein Großteil der alkoholischen Fettlebern bildet sich unter Alkoholkarenz oder sogar Alkoholreduktion zurück. Die alkoholische Hepatitis, ein klinisches Syndrom mit hoher Mortalität, führt ohne Alkoholkarenz innerhalb von Tagen und Wochen zum Tode. Darüber hinaus ist selbst die Leberfibrose (perivenös und perisinusoidal) unter Alkoholkarenz rückbildungsfähig. Bei allen Formen der fortgeschrittenen ALE (kompensiert und nicht-kompensierte Leberzirrhose) wird die Mortalität durch Alkoholkarenz oder signifikante Reduktion im Gegensatz zum fortgesetzten Alkoholkonsum signifikant verringert. Selbst Patienten mit alkoholischer Leberzirrhose können über mehr als 20 Jahre ohne Komplikationen weiterleben, wenn sie komplett auf Alkohol verzichten. Schlussfolgerung: Im Vergleich zu Leberzirrhose anderer Ätiologie, wie zum Beispiel Zirrhosen, die durch das Hepatitis-B Virus oder das Hepatitis-C Virus verursacht sind, haben alkoholische Leberzirrhosen unter Alkoholkarenz eine wesentlich bessere Prognose. Damit ist Alkoholkarenz eine gute Therapie und der Erfolg jeder anderen neuen Therapie muss mit Alkoholkarenz verglichen werden.

Disparities in Time to Treatment of Hepatocellular Carcinoma in Patients with Hepatitis B Virus versus Hepatitis C Virus

2017 ◽  
Vol 05 (03) ◽  
Author(s):  
Jennifer Wu ◽  
Tsivia Hochman ◽  
Judith D Goldberg ◽  
Jafar Al Mondhiry ◽  
Bennal Perkins ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Time To Treatment ◽  
B Virus ◽  
Virus Versus

scholarly journals Algorithms for the Testing of Tissue Donors for Human Immunodeficiency Virus, Hepatitis B Virus, and Hepatitis C Virus

2020 ◽  
pp. 1-10
Author(s):  
Axel Pruß ◽  
Akila Chandrasekar ◽  
Jacinto Sánchez-Ibáñez ◽  
Sophie Lucas-Samuel ◽  
Ulrich Kalus ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Tissue Donors ◽  
Occult Hbv Infection ◽  
Occult Hbv ◽  
B Virus ◽  
Immunodeficiency Virus

<b><i>Background:</i></b> Although transmission of pathogenic viruses through human tissue grafts is rare, it is still one of the most serious dreaded risks of transplantation. Therefore, in addition to the detailed medical and social history, a comprehensive serologic and molecular screening of the tissue donors for relevant viral markers for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) is necessary. In the case of reactive results in particular, clear decisions regarding follow-up testing and the criteria for tissue release must be made. <b><i>Methods:</i></b> Based on the clinical relevance of the specific virus markers, the sensitivity of the serological and molecular biological methods used and the application of inactivation methods, algorithms for tissue release are suggested. <b><i>Results:</i></b> Compliance with the preanalytical requirements and assessment of a possible hemodilution are mandatory requirements before testing the blood samples. While HIV testing follows defined algorithms, the procedures for HBV and HCV diagnostics are under discussion. Screening and decisions for HBV are often not as simple, e.g., due to cases of occult HBV infection, false-positive anti-HBc results, or early window period positive HBV NAT results. In the case of HCV diagnostics, modern therapies with direct-acting antivirals, which are often associated with successful treatment of the infection, should be included in the decision. <b><i>Conclusion:</i></b> In HBV and HCV testing, a high-sensitivity virus genome test should play a central role in diagnostics, especially in the case of equivocal serology, and it should be the basis for the decision to release the tissue. The proposed test algorithms and decisions are also based on current European recommendations and standards for safety and quality assurance in tissue and cell banking.

scholarly journals Hepatitis B Virus, Hepatitis C Virus and Human T Lymphotropic Type I Among Institutionalized Mentally Retarded Patients in Okinawa, Japan

1992 ◽  
Vol 2 (1) ◽  
pp. 1-5 ◽  
Author(s):  
Jun Hayashi ◽  
Koya Nakashima ◽  
Miki Hirata ◽  
Eriko Yoshimura ◽  
Akinori Noguchi ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Mentally Retarded ◽  
Type I ◽  
Virus Hepatitis ◽  
B Virus
Sign in / Sign up

Export Citation Format

Share Document